Performance of the QPLEXTM Alz plus assay, a novel multiplex kit for screening cerebral amyloid deposition
Background: Alzheimer's disease (AD) is an irreversible neurodegenerative disease characterized by the hallmark finding of cerebral amyloid deposition. Many researchers have tried to predict the existence of cerebral amyloid deposition by using easily accessible blood plasma samples, but the effectiveness of such strategies remains controversial.
Methods: We developed a new multiplex kit, the QPLEXTM Alz plus assay kit, which uses proteomics-based blood biomarkers to prescreen for cerebral amyloid deposition. A total of 300 participants who underwent Pittsburgh compound B (PiB)-positron emission tomography (PET) which allows imaging of cerebral amyloid deposition were included in this study. We compared the levels of QPLEXTM biomarkers between patients who were classified as PiB-negative or PiB-positive, regardless of their cognitive function. Logistic regression analysis followed by receiver operating characteristic (ROC) curve analysis was performed. The kit accuracy was tested using a randomized sample selection method.
Results: The results obtained using our assay kit reached 89.1% area under curve (AUC) with 80.0% sensitivity and 83.0% specificity. Further validation of the QPLEXTM Alz plus assay kit using a randomized sample selection method showed an average accuracy of 81.5%.
Conclusions: Our QPLEXTM Alz plus assay kit provides preliminary evidence that it can be used as blood marker to predict cerebral amyloid deposition but independent validation is needed.
Figure 1
Figure 1
Figure 1
This is a list of supplementary files associated with this preprint. Click to download.
Supplementary Fig. 1. Comparison of PiB- vs. PiB+ among CN or MCI. (A) Logistic regression analysis followed by ROC curve analysis among the CN group and comparison of ROC curve analysis. (B) Logistic regression analysis followed by ROC curve analysis among the MCI group and comparison of ROC curve analysis. AUC, area under curve; PV, predictive values; SE, standard error; CI, confidence interval.
Posted 18 Dec, 2020
On 06 Jan, 2021
On 30 Nov, 2020
On 29 Nov, 2020
On 29 Nov, 2020
On 29 Nov, 2020
Posted 23 Nov, 2020
On 23 Nov, 2020
On 22 Nov, 2020
On 22 Nov, 2020
On 22 Nov, 2020
On 30 Oct, 2020
On 24 Sep, 2020
On 23 Sep, 2020
On 23 Sep, 2020
On 02 Aug, 2020
On 02 Jul, 2020
On 01 Jul, 2020
On 26 Jun, 2020
On 25 Jun, 2020
Performance of the QPLEXTM Alz plus assay, a novel multiplex kit for screening cerebral amyloid deposition
Posted 18 Dec, 2020
On 06 Jan, 2021
On 30 Nov, 2020
On 29 Nov, 2020
On 29 Nov, 2020
On 29 Nov, 2020
Posted 23 Nov, 2020
On 23 Nov, 2020
On 22 Nov, 2020
On 22 Nov, 2020
On 22 Nov, 2020
On 30 Oct, 2020
On 24 Sep, 2020
On 23 Sep, 2020
On 23 Sep, 2020
On 02 Aug, 2020
On 02 Jul, 2020
On 01 Jul, 2020
On 26 Jun, 2020
On 25 Jun, 2020
Background: Alzheimer's disease (AD) is an irreversible neurodegenerative disease characterized by the hallmark finding of cerebral amyloid deposition. Many researchers have tried to predict the existence of cerebral amyloid deposition by using easily accessible blood plasma samples, but the effectiveness of such strategies remains controversial.
Methods: We developed a new multiplex kit, the QPLEXTM Alz plus assay kit, which uses proteomics-based blood biomarkers to prescreen for cerebral amyloid deposition. A total of 300 participants who underwent Pittsburgh compound B (PiB)-positron emission tomography (PET) which allows imaging of cerebral amyloid deposition were included in this study. We compared the levels of QPLEXTM biomarkers between patients who were classified as PiB-negative or PiB-positive, regardless of their cognitive function. Logistic regression analysis followed by receiver operating characteristic (ROC) curve analysis was performed. The kit accuracy was tested using a randomized sample selection method.
Results: The results obtained using our assay kit reached 89.1% area under curve (AUC) with 80.0% sensitivity and 83.0% specificity. Further validation of the QPLEXTM Alz plus assay kit using a randomized sample selection method showed an average accuracy of 81.5%.
Conclusions: Our QPLEXTM Alz plus assay kit provides preliminary evidence that it can be used as blood marker to predict cerebral amyloid deposition but independent validation is needed.
Figure 1
Figure 1
Figure 1